A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome | MicrobiomeTrials← Back to trialsNCT05898620
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-06-13Est. Completion: 2029-12
Enrollment target: 33 participants Locations- University of Alabama at Birmingham, Birmingham, Alabama, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Nicklaus Children's Hospital Research Institute, Miami, Florida, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Montefiore Medical Center, New York, New York, United States
- UNC at Chapel Hill, Chapel Hill, North Carolina, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Texas Children's Hospital, Houston, Texas, United States
- The Children's Hospital at Westmead, Sydney, New South Wales, Australia
- Royal Hospital for Children and Young People, Edinburgh, United Kingdom
Other microbiome trials you might be interested in
Rett Syndrome
Rett syndrome (RTT) is a rare genetic neurodevelopmental disorder caused primarily by mutations in the MECP2 gene, leadi…
Fortaleza, BrazilCompleted Jun 2027
Rett Syndrome
The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study par…
Little Rock, United StatesEst. completion Aug 1, 2028
Manchester University NHS Foundation Trust, Manchester, United Kingdom